Coronavirus Disease 2019 Vaccine for Children in China: When to Start? Mandatory or Voluntary?
The COVID-19 pandemic has continued to expand globally, with the emergence of more transmissible variants raising concerns about the severity of potential second waves. Effective vaccines remain a critical tool in controlling the pandemic, and their development and distribution have been prioritized worldwide. As of April 4, 2021, over 604 million vaccine doses had been administered globally, according to the World Health Organization. In China, five vaccines are in phase III clinical trials, including CoronaVac by Sinovac and ZF2001 by Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. While vaccination campaigns have primarily targeted healthcare personnel and adults, the question of when and how to vaccinate children remains a pressing issue.
The Need for Vaccinating Children
Achieving herd immunity is a key goal in pandemic control, and vaccinating children is essential to this effort. Herd immunity is estimated to require immunization of approximately 60% of the population. Children, while less likely to develop severe forms of COVID-19, can still contribute to the spread of the virus, especially with the emergence of faster-spreading variants. Although there is no direct evidence of transmission from children to adults, the risk of family cluster transmission and the challenges of maintaining hygiene practices in young children highlight the importance of including them in vaccination strategies.
Vaccine Development and Clinical Trials for Children
Vaccine development for children has lagged behind that for adults due to safety concerns and the need for tailored clinical trials. Early adult trials raised concerns about “enhanced disease” in vaccinated individuals who later became infected, as well as thromboembolic events linked to certain vaccines. Five vaccine platforms are being explored for COVID-19: live attenuated virus, inactivated virus, subunit vaccine, viral vector-based vaccine, and RNA/DNA vaccine. Pfizer-BioNTech and Moderna have initiated clinical trials for adolescents, with studies also underway in China for children aged 3 to 17 years. Sinovac’s inactivated vaccine, which has shown safety and stability in previous trials, is a leading candidate for pediatric use in China.
Safety and Effectiveness Considerations
Safety and effectiveness are paramount in pediatric vaccine development. mRNA vaccines, such as those by Pfizer and Moderna, offer high immunogenicity and rapid development potential but require ultra-cold storage, posing logistical challenges. Inactivated vaccines, like Sinovac’s, are stable and based on pre-existing technology but may require booster shots to maintain immunity. The ongoing clinical trials in China aim to address these issues, with primary completion dates set for 2021. The results of these trials will be critical in determining the timing and strategy for vaccinating children in China.
Vaccine Hesitancy and Public Acceptance
Vaccine hesitancy is a global issue, reported in over 90% of countries. In China, public acceptance of COVID-19 vaccines is influenced by factors such as vaccine effectiveness, side effects, and the proportion of acquaintances vaccinated. Studies have shown that high effectiveness, long protective duration, and information from authoritative sources play significant roles in shaping public preferences. While China has a strong tradition of school immunization mandates, the decision to make COVID-19 vaccination mandatory for children remains contentious.
Mandatory vs. Voluntary Vaccination
The debate over mandatory versus voluntary vaccination for children involves medical, ethical, and socio-economic considerations. Supporters argue that mandatory vaccination is necessary to control the spread of the virus, protect children from severe forms of COVID-19, and achieve herd immunity. Opponents raise concerns about the safety and effectiveness of vaccines, differing immune responses in children, and ethical considerations. Drawing lessons from other vaccines, such as influenza, may help optimize COVID-19 vaccine administration policies.
Vaccination Strategies for Different Epidemic Situations
Countries and regions with varying epidemic situations may adopt different vaccination strategies for children. In China, where the epidemic is well controlled, voluntary vaccination may be a suitable approach. In areas with severe outbreaks, compulsory policies could be more effective. Special considerations are needed for subgroups of children, such as those with autoimmune diseases or those receiving immunosuppressive treatments. Even with widespread vaccination, public health measures like mask-wearing and social distancing should continue to play a role in controlling the pandemic.
Conclusion
The vaccination of children for COVID-19 is an essential step in controlling the pandemic and achieving herd immunity. While safety and effectiveness remain critical concerns, ongoing clinical trials in China and globally are expected to provide the necessary data to guide vaccination strategies. The decision to make vaccination mandatory or voluntary will depend on a range of factors, including the severity of the epidemic, public acceptance, and ethical considerations. Collaborative efforts by governments, health policymakers, and healthcare professionals will be crucial in ensuring the successful implementation of pediatric vaccination programs. As the world continues to grapple with the challenges of COVID-19, vaccinating children represents a vital component of the global response to the pandemic.
doi.org/10.1097/CM9.0000000000001779
Was this helpful?
0 / 0